Managing Toxicities of Zanidatamab and Trastuzumab in Upper GI Cancer
Key Points
- Zanidatamab is now the new standard of care treatment option for HER2-positive GE junction, gastric, and esophageal adenocarcinoma.
- Dosing is fixed for zanidatamab depending on the weight, and can be combined with chemo and immunotherapy. Stepdown dosing should be considered if side effects become serious.
- Other treatment options include trastuzumab plus chemotherapy and trastuzumab deruxtecan.
- All three therapies are associated with side effects, including diarrhea, which can be treated upfront with prophylactic antidiarrheals, and infusion related reactions. The most serious toxicity, interstitial lung disease, should be treated as early as possible.
In this Tox Check episode, co-hosts of the Oncology Brothers podcast — Rahul Gosain, MD, MBA, of Wilmot Cancer Institute, and Rohit Gosain, MD, of Roswell Park Comprehensive Cancer Center — spoke with Shruti Patel, MD, of Stanford University School of Medicine, and Samuel Cytryn, MD, of Memorial Sloan Kettering Cancer Center, about HER2-targeted therapies for upper gastrointestinal malignancies, focusing primarily on zanidatamab and trastuzumab. The experts reviewed the indications and side effects, offering clinical pearls for effective management.
The treatment of upper GI malignancies is driven by biomarkers, including HER2 status, PDL1 score, Claudin 18.2, and MSI status. For HER2-positive GE junction, gastric, and esophageal adenocarcinoma, zanidatamab is the new standard of care treatment option, based on findings from HORIZEN GEA 001. Other therapeutic options are trastuzumab plus chemotherapy and trastuzumab deruxtecan (T-DXd).
Trastuzumab and Zanidatamab
For trastuzumab, a monoclonal antibody, the loading dose is 8 mg/kg and maintenance is 6 mg/kg for three weeks until progression. The most prevalent side effects are cardiac symptoms and infusion reactions, according to Dr. Patel, who recommends patients undergo an echocardiogram every three months.
Infusion reactions are common; therefore, it’s critical to educate patients on what to expect. “When patients are in the chair, it’s scary to start developing fever and chills, especially in first-line treatment.” Interstitial lung disease (ILD), while rare, does occur and can be “extremely harmful,” said Dr. Patel.
With zanidatamab, a bitropic antibody, dosing is 20 mg/kg every two weeks. Cardiotoxicity and infusion reactions are common, along with diarrhea, which can be “robust,” said Dr. Cytryn. In these patients, prophylactic antidiarrheals such as Imodium (loperamide hydrochloride) can be administered twice a day for the first week to help decrease the extent of the diarrhea.
If there is no progress, patients are urged to reach out to their provider, Dr. Cytryn said. “I like to say, when I see you in 2 weeks, I don’t want any surprises. I want to know exactly what’s happened, because if you’re [taking] Imodium twice a day and not experiencing relief, we need to fold in Lomotil (diphenoxylate/atropine) and stronger anti-diarrheals more quickly, not waiting for it to get out of hand.”
Treating Infusions With Pre-Medication
Another critical component with zanidatamab is administering pre-medications, said Dr. Patel, noting that infusion-related reactions occur in about 30% of patients. “That’s not trivial at all.”
Incorporating acetaminophen, antihistamine, and steroid into the treatment plan and ensuring patients fill them prior to treatment can ease the experience both during and after infusion. If an infusion reaction does occur, it’s important to “stop, make sure they’re medicated, and restart at 50%,” Dr. Patel said.
Echocardiogram
Given the cardiac risks, echocardiagram is recommended at baseline in patients taking zanidatamab, and every three months with trastuzumab. It becomes more nuanced, however, in those with metastatic gastroesophageal cancer. “We have to think about the big picture and what overall survival looks like,” Dr. Patel stated. “When we’re talking about trastuzumab or HER2-targeted agents in breast cancer, for example, where survivorship is a bigger consideration, they have to get it” to help prevent cardiomyopathy because “once they’re cured, they have the rest of their life to live.”
As with all situations involving cancer treatment, it’s critical to “find that medium which will balance the side effect profile and efficacy,” said Dr. Rohit Gosain. “We have to utilize our best agents upfront,” while carefully considering toxicity.
Stepdown Dosing
Stepdown dosing is also imperative, but it can meet resistance. “Patients get very nervous that it’s not going to be as effective,” said Dr. Cytryn. “I haven’t seen any data of meaningful consequence” to support it.
If side effects become severe, providers should immediately assess whether to continue treatment, said Dr. Rahul Gosain. “We’re trying to buy more time and keep quality of life at the center. If you have to decrease the dose to mitigate side effects, that’s important.”
T-DXd
For T-DXd, an antibody-drug conjugate, standard dosing is 6.4 mg/kg every three weeks in the upper GI space. “It’s essentially a sophisticatedly packed chemotherapy,” said Dr. Patel, meaning patients “will still feel the classic side effects of chemo.” Toxicities that can present include fatigue, alopecia, and cytopenias, along with ILD, which can be treated with steroids.
Detecting ILD as soon as possible is vital, according to Dr. Patel, who advised asking targeted questions. For example, instead of asking if a patient is short of breath, she will ask if they experience it more while walking up the stairs or going on a walk. And if they’re not going for walks, is it due to nausea, or are they getting winded easily? “We need to ask very specific questions to elicit the ILD out,” she said.